Fabad Journal of Pharmaceutical Sciences, cilt.26, sa.1, ss.47-56, 2001 (Scopus)
Fluvoxamine, which specifically inhibits the serotonin reuptake, is an antidepressant compound from the series of 2-aminoethyloximethers of arylalkylketones, which is a newly developed and second generation antidepressant class. It is used in the treatment of psychiatric disorders such as depression, obsessive-compulsive and panic; aggression and posttraumatic stress disorders, bulimia and recently alcohol and drug abuse. In this article, the physicochemical properties, assay methods, pharmacological properties, pharmacokinetics and bioavailability of fluvoxamine and drug interactions are outlined.